$647.77 Million in Sales Expected for Cooper Companies Inc (NYSE:COO) This Quarter
Brokerages forecast that Cooper Companies Inc (NYSE:COO) will post sales of $647.77 million for the current quarter, Zacks reports. Ten analysts have issued estimates for Cooper Companies’ earnings, with estimates ranging from $645.60 million to $650.20 million. Cooper Companies reported sales of $628.10 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 3.1%. The business is scheduled to report its next quarterly earnings results after the market closes on Thursday, March 5th.
According to Zacks, analysts expect that Cooper Companies will report full-year sales of $2.80 billion for the current year, with estimates ranging from $2.79 billion to $2.81 billion. For the next financial year, analysts expect that the company will report sales of $2.98 billion, with estimates ranging from $2.96 billion to $3.01 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Cooper Companies.
Cooper Companies (NYSE:COO) last posted its quarterly earnings data on Thursday, December 5th. The medical device company reported $3.30 earnings per share for the quarter, topping the consensus estimate of $3.27 by $0.03. The business had revenue of $691.60 million during the quarter, compared to the consensus estimate of $683.83 million. Cooper Companies had a net margin of 17.59% and a return on equity of 17.38%. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.87 earnings per share.
COO stock traded up $0.34 during trading on Tuesday, hitting $353.31. The company had a trading volume of 195,721 shares, compared to its average volume of 284,985. The firm has a market capitalization of $17.47 billion, a price-to-earnings ratio of 37.83, a P/E/G ratio of 2.54 and a beta of 0.89. The business has a 50 day moving average of $341.43 and a 200 day moving average of $316.71. Cooper Companies has a fifty-two week low of $274.77 and a fifty-two week high of $365.68. The company has a current ratio of 1.05, a quick ratio of 0.59 and a debt-to-equity ratio of 0.35.
The firm also recently declared a semi-annual dividend, which was paid on Monday, February 10th. Shareholders of record on Thursday, January 23rd were issued a $0.03 dividend. The ex-dividend date of this dividend was Wednesday, January 22nd. Cooper Companies’s payout ratio is 0.49%.
In other Cooper Companies news, Director Michael Kalkstein sold 9,500 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $320.35, for a total value of $3,043,325.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jody S. Lindell sold 3,500 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $321.01, for a total transaction of $1,123,535.00. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp lifted its position in shares of Cooper Companies by 1.5% in the fourth quarter. State Street Corp now owns 2,114,314 shares of the medical device company’s stock worth $679,308,000 after purchasing an additional 31,882 shares in the last quarter. Veritas Asset Management LLP lifted its position in shares of Cooper Companies by 0.9% in the third quarter. Veritas Asset Management LLP now owns 990,602 shares of the medical device company’s stock worth $294,209,000 after purchasing an additional 9,300 shares in the last quarter. FIL Ltd lifted its position in shares of Cooper Companies by 18.5% in the fourth quarter. FIL Ltd now owns 938,718 shares of the medical device company’s stock worth $301,601,000 after purchasing an additional 146,784 shares in the last quarter. Amundi Pioneer Asset Management Inc. lifted its position in shares of Cooper Companies by 83.5% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 915,089 shares of the medical device company’s stock worth $294,008,000 after purchasing an additional 416,382 shares in the last quarter. Finally, Marshall Wace North America L.P. lifted its position in shares of Cooper Companies by 56.1% in the fourth quarter. Marshall Wace North America L.P. now owns 813,443 shares of the medical device company’s stock worth $261,352,000 after purchasing an additional 292,238 shares in the last quarter. 96.30% of the stock is owned by institutional investors.
About Cooper Companies
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Further Reading: Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.